Zimmer Biomet (NYSE:ZBH) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says

Zimmer Biomet (NYSE:ZBH) had its price objective hoisted by analysts at Wells Fargo & Company from $93.00 to $98.00 in a research note issued on Wednesday,Benzinga reports. The brokerage presently has an “equal weight” rating on the medical equipment provider’s stock. Wells Fargo & Company‘s price target suggests a potential upside of 3.01% from the stock’s current price.

Several other brokerages have also recently weighed in on ZBH. Robert W. Baird reiterated a “neutral” rating and issued a $100.00 price objective (down from $117.00) on shares of Zimmer Biomet in a report on Tuesday, December 16th. Barclays decreased their price target on Zimmer Biomet from $112.00 to $105.00 and set an “underweight” rating on the stock in a research note on Wednesday, November 5th. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a research report on Tuesday. Evercore raised shares of Zimmer Biomet from an “in-line” rating to an “outperform” rating and upped their target price for the company from $94.00 to $120.00 in a research report on Monday, January 5th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Zimmer Biomet in a research note on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, nine have given a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $106.20.

Zimmer Biomet Stock Down 0.5%

Shares of ZBH stock opened at $95.14 on Wednesday. The stock’s 50-day simple moving average is $90.05 and its 200-day simple moving average is $95.64. The firm has a market capitalization of $18.85 billion, a PE ratio of 26.87, a P/E/G ratio of 2.71 and a beta of 0.62. Zimmer Biomet has a fifty-two week low of $84.59 and a fifty-two week high of $114.44. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.39 and a current ratio of 1.98.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Tuesday, February 10th. The medical equipment provider reported $2.42 EPS for the quarter, topping analysts’ consensus estimates of $2.38 by $0.04. The business had revenue of $2.24 billion for the quarter, compared to analysts’ expectations of $2.22 billion. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The business’s revenue was up 10.9% on a year-over-year basis. During the same quarter last year, the company earned $2.31 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. Equities analysts expect that Zimmer Biomet will post 8.22 earnings per share for the current year.

Institutional Investors Weigh In On Zimmer Biomet

Several large investors have recently modified their holdings of the stock. M&T Bank Corp boosted its position in Zimmer Biomet by 15,705.6% during the fourth quarter. M&T Bank Corp now owns 3,571,595 shares of the medical equipment provider’s stock worth $321,158,000 after purchasing an additional 3,548,998 shares in the last quarter. Dodge & Cox raised its stake in shares of Zimmer Biomet by 12.9% during the 2nd quarter. Dodge & Cox now owns 22,097,463 shares of the medical equipment provider’s stock worth $2,015,510,000 after buying an additional 2,533,009 shares during the last quarter. Norges Bank purchased a new stake in shares of Zimmer Biomet in the 2nd quarter worth about $225,867,000. Franklin Resources Inc. grew its stake in Zimmer Biomet by 43.2% in the 4th quarter. Franklin Resources Inc. now owns 6,685,987 shares of the medical equipment provider’s stock valued at $601,204,000 after acquiring an additional 2,017,857 shares during the last quarter. Finally, AQR Capital Management LLC increased its holdings in Zimmer Biomet by 276.6% during the 2nd quarter. AQR Capital Management LLC now owns 1,300,593 shares of the medical equipment provider’s stock valued at $118,627,000 after acquiring an additional 955,284 shares in the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet News Roundup

Here are the key news stories impacting Zimmer Biomet this week:

• Positive Sentiment: Q4 beat and buyback — ZBH topped estimates on revenue and EPS, and the company announced a new buyback that pushed the stock higher after results. Positive near-term cash-return and sales momentum were highlighted. Article Title
• Positive Sentiment: Buy-side upgrade — BTIG Research issued a “Buy” on ZBH, supporting upside sentiment among some investors. Article Title
• Positive Sentiment: Index inclusion/lift — Coverage noted ZBH’s results helped lift the Russell 1000 Healthcare index, signaling industry-level recognition of the quarter. Article Title
• Neutral Sentiment: Analyst price-target moves — Citigroup and Wells Fargo raised ZBH price targets to $98 while keeping neutral/equal-weight ratings, which signals modest upside but not a broad bullish repositioning. Article Title
• Neutral Sentiment: Hold reaffirmation — Needham reaffirmed a “Hold” on ZBH, reflecting mixed analyst conviction despite the beat. Article Title
• Neutral Sentiment: Sector context — A MarketBeat piece comparing healthcare earnings highlights peers (e.g., AstraZeneca) outperforming in profit growth, which provides cross-checks for relative performance but is not company-specific. Article Title
• Negative Sentiment: Guidance caution from salesforce changes — Deep-dive coverage flagged a U.S. salesforce overhaul that prompted management to strike a measured tone on FY26 guidance, introducing execution risk that likely weighs on the stock today. Article Title
• Negative Sentiment: Measured tone on guidance in the earnings call — Transcripts and coverage emphasize that while Q4 beat, management set cautious FY26 commentary and guidance range, which may limit investor upside until execution is clearer. Article Title

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.